---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-200220"
form_type: "8-K"
ticker: "GRTX"
cik: "0001563577"
company_name: "Galera Therapeutics, Inc."
filed_at: "2024-08-14T23:59:59+00:00"
generated_at: "2026-05-31T09:19:24.344963+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Galera Therapeutics board approves dissolution; CFO and CLO positions eliminated

## Summary
- Board unanimously approved Plan of Liquidation and Dissolution; special stockholder meeting on or around Oct 17, 2024.
- Workforce reduced to 3 employees; CFO Chris Degnan and CLO Jennifer Evans Stacey positions cut effective Aug 31, 2024.
- Q2 2024 net loss $4.1M ($0.07 per share) vs $20.7M ($0.48) in Q2 2023; R&D expenses fell to $1.4M.
- Cash and equivalents $10.7M as of June 30, 2024; expects to fund dissolution costs for at least 12 months.
- No suitable strategic alternatives found; may still sell pipeline assets, proceeds to be distributed to stockholders.

## SEC filing metadata
- accession: 0001193125-24-200220
- form_type: 8-K
- ticker: GRTX
- cik: 0001563577
- company_name: Galera Therapeutics, Inc.
- filed_at: 2024-08-14T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1563577/000119312524200220/0001193125-24-200220-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1563577/000119312524200220/d879192d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-200220
- JSON: https://secwatch.observer/filing/0001193125-24-200220.json
- Plain text: https://secwatch.observer/filing/0001193125-24-200220.txt

## Key facts
- Executive change
  Christopher Degnan departed as Chief Financial Officer at Galera Therapeutics, Inc..
  - Action: position eliminated
  - Role: Chief Financial Officer
  source text: On August 8, 2024, the Company notified Christopher Degnan, the Company’s Chief Financial Officer and principal financial officer, that his position is being eliminated, effective August 31, 2024, in order to save costs as the Company moves forward with the dissolution of the Company, as described below.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1563577/000119312524200220/0001193125-24-200220-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.